European Medical Journal

AI-Driven Identification of High-Risk Patients with COPD for Biologic Therapy: Pathway Development Opportunities

Biologic therapies targeting eosinophilic inflammation hold promise for COPD management. Realising their benefits will ...
European Medical Journal

Challenges in Advanced Lung Disease: Perspectives on Alpha 1 Antitrypsin Deficiency and Bronchiectasis

One of the most common genetic diseases, AATD, involves the retention of misfolded alpha 1 antitrypsin (AAT) in hepatocytes, ...
Sportschosun on MSN

4 hospitals at Hallym University Medical Center, the highest grade in 3 categories of chronic obstru...

Hanlim University Medical Center (Director Kim Yong-sun) obtained the highest grade in the adequacy evaluation of chronic ...
The American Journal of Managed Care

Brensocatib Improves Outcomes in Non-Cystic Fibrosis Bronchiectasis With or Without Comorbid COPD

Brensocatib, a DPP1 inhibitor, is the first FDA-approved therapy for non-cystic fibrosis bronchiectasis, showing significant clinical and structural benefits. The ASPEN trial demonstrated that ...
Pulmonology Advisor

MACE in COPD: Risk Stratification Improved Using Tool Combining CVRS, CACS

A tool combining CV risk score (CVRS) and coronary artery calcium score (CACS) facilitates stratification of patients with COPD at risk for MACE.
AHA/ASA Journals

State of the Art: Evaluation and Medical Management of Nonobstructive Coronary Artery Disease in Patients With Chest Pain: A Scientific Statement From the American Heart ...

Risk stratification of patients with chest pain has traditionally focused on identifying obstructive coronary artery disease (CAD). Using this traditional approach, many symptomatic individuals are ...